Open Access

Myeloid‑derived suppressor cells as targets of emerging therapies and nanotherapies (Review)

  • Authors:
    • Dileep Kumar
    • Victor Carlos Da Silva
    • Natalia Lemos Chaves
  • View Affiliations

  • Published online on: June 25, 2024     https://doi.org/10.3892/mi.2024.170
  • Article Number: 46
  • Copyright : © Kumar et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer (BC) is the leading cause of cancer‑related mortality among women worldwide. Immunotherapies are a promising approach in cancer treatment, particularly for aggressive forms of BC with high mortality rates. However, the current eligibility for immunotherapy remains limited to a limited fraction of patients with BC. Myeloid‑derived suppressor cells (MDSCs), originating from myeloid cells, are known for their dual role in immunosuppression and tumor promotion, significantly affecting patient outcomes by fostering the formation of premetastatic niches. Consequently, targeting MDSCs has emerged as a promising avenue for further exploration in therapeutic interventions. Leveraging nanotechnology‑based drug delivery systems, which excel in accumulating drugs within tumors via passive or active targeting mechanisms, are a promising strategy for the use of MDSCs in the treatment of BC. The present review discusses the immunosuppressive functions of MDSCs, their role in BC, and the diverse strategies for targeting them in cancer therapy. Additionally, the present review discusses future advancements in BC treatments focusing on MDSCs. Furthermore, it elucidates the mechanisms underlying MDSC activation, recruitment and differentiation in BC progression, highlighting the clinical characteristics that render MDSCs suitable candidates for the therapy and targeted nanotherapy of BC.
View Figures
View References

Related Articles

Journal Cover

September-October 2024
Volume 4 Issue 5

Print ISSN: 2754-3242
Online ISSN:2754-1304

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kumar D, Da Silva VC and Chaves NL: Myeloid‑derived suppressor cells as targets of emerging therapies and nanotherapies (Review). Med Int 4: 46, 2024.
APA
Kumar, D., Da Silva, V.C., & Chaves, N.L. (2024). Myeloid‑derived suppressor cells as targets of emerging therapies and nanotherapies (Review). Medicine International, 4, 46. https://doi.org/10.3892/mi.2024.170
MLA
Kumar, D., Da Silva, V. C., Chaves, N. L."Myeloid‑derived suppressor cells as targets of emerging therapies and nanotherapies (Review)". Medicine International 4.5 (2024): 46.
Chicago
Kumar, D., Da Silva, V. C., Chaves, N. L."Myeloid‑derived suppressor cells as targets of emerging therapies and nanotherapies (Review)". Medicine International 4, no. 5 (2024): 46. https://doi.org/10.3892/mi.2024.170